Ovarian Cancer: This Targeted Treatment is Already Changing the Game for Many Patients

For the first time in twenty years, a groundbreaking medical advancement is transforming the management of resistant ovarian cancer. Mirvetuximab soravtansine, a highly promising targeted therapy, extends the life expectancy of patients while preserving the quality of their daily lives. This is profoundly reassuring news for many women and their loved ones.